Christopher M. Jewell's experience spans over 20 years, including as founder of multiple companies, Chief Scientific Officer at Cartesian Therapeutics, a consultant with the Boston Consulting Group (New York), an advisor to dozens of start-ups and large pharma companies, and as Institute Professor of Translational Engineering at the University of Maryland. He is a recognized KOL in autoimmune disease and new immunotherapy technologies whose work has been supported by $37M+ in non-dilutive funding and resulted in over 150 patents and papers in top journals, including Nature, Nature Biotechnology, Nature Medicine, Nature Materials, Science Translational Medicine, and others. In service and policy, Dr. Jewell is a member of the PhRMA Advisory Committee, has served as a member of White House OSTP committees, and as a regular panelist and contributor to the HHS/NIH. He is an elected Fellow of numerous societies and has received over 50 professional awards. Some of these include the Damon Runyon Cancer Foundation Innovator Award, and being honored by the White House with the Presidential Early Career Award for Scientists and Engineers (PECASE)--the United States' highest honor to such scientists. Dr. Jewell carried out his postdoctoral training as a Ragon Fellow with Dr. Darrell Irvine at MIT and as a Visiting Scientist at Harvard with Dr. Dan Barouch (Division of Vaccine Research). He graduated from Lehigh University (high honors), earning dual degrees in Chemical Engineering and Molecular Biology, then received his PhD in Chemical Engineering from the University of Wisconsin. His thesis focused on RNA and DNA delivery for gene therapy.